The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform
Adam Finn - One of the best experts on this subject based on the ideXlab platform.
-
Adverse effects and sero-responses to an acellular pertussis/diphtheria/Tetanus Vaccine when combined with Haemophilus influenzae type b Vaccine in an accelerated schedule.
European journal of pediatrics, 1999Co-Authors: F Bell, Paul T. Heath, Jenny M. Maclennan, F Shackley, N Shearstone, Linda Diggle, C Thornton, H Griffiths, Er Moxon, Adam FinnAbstract:Acellular pertussis Vaccines provide protection against pertussis with few adverse effects. Differences in the reactogenicity and immunogenicity of available pertussis Vaccines may be influenced by the immunisation schedule employed. We assessed responses to an acellular pertussis, diphtheria, Tetanus Vaccine mixed with Haemophilus influenzae type b (Hib) Vaccine, (PRP-T) given at age 2, 3 and 4 months. Parents kept a symptom diary for 3 days after each immunisation. Antibodies to diphtheria, Tetanus, pertussis toxin and filamentous haemagglutinin were measured by enzyme immunoassay at 2 and 5 months. Results were compared with historical controls who received a combination whole-cell pertussis, diphtheria, Tetanus/PRP-T Vaccine in the same schedule. A total of 262 infants were recruited, of whom 251 were fully evaluated after three doses of Vaccine. Systemic and most local reactions were less frequent following the acellular combination. Fever ≥38°C was reported after only 0.6% of doses. Redness or swelling ≥2.5 cm were unusual after the first two doses (2–5%), but rates rose to 13% after the third dose. Antibody responses to diphtheria and Tetanus toxoids were lower, while those to pertussis antigens were higher, more uniform and less attenuated by pre-immunisation antibody than in infants who received the whole-cell combination. All infants achieved protective antibody titres of at least 0.1 IU/ml for diphtheria and 0.01 IU/ml for Tetanus.
-
Adverse effects and sero-responses to an acellular pertussis/diphtheria/Tetanus Vaccine when combined with Haemophilus influenzae type b Vaccine in an accelerated schedule
European Journal of Pediatrics, 1999Co-Authors: F Bell, F Shackley, N Shearstone, Linda Diggle, C Thornton, H Griffiths, Er Moxon, P. Heath, J. Maclennan, Adam FinnAbstract:Acellular pertussis Vaccines provide protection against pertussis with few adverse effects. Differences in the reactogenicity and immunogenicity of available pertussis Vaccines may be influenced by the immunisation schedule employed. We assessed responses to an acellular pertussis, diphtheria, Tetanus Vaccine mixed with Haemophilus influenzae type b (Hib) Vaccine, (PRP-T) given at age 2, 3 and 4 months. Parents kept a symptom diary for 3 days after each immunisation. Antibodies to diphtheria, Tetanus, pertussis toxin and filamentous haemagglutinin were measured by enzyme immunoassay at 2 and 5 months. Results were compared with historical controls who received a combination whole-cell pertussis, diphtheria, Tetanus/PRP-T Vaccine in the same schedule. A total of 262 infants were recruited, of whom 251 were fully evaluated after three doses of Vaccine. Systemic and most local reactions were less frequent following the acellular combination. Fever ≥38°C was reported after only 0.6% of doses. Redness or swelling ≥2.5 cm were unusual after the first two doses (2–5%), but rates rose to 13% after the third dose. Antibody responses to diphtheria and Tetanus toxoids were lower, while those to pertussis antigens were higher, more uniform and less attenuated by pre-immunisation antibody than in infants who received the whole-cell combination. All infants achieved protective antibody titres of at least 0.1 IU/ml for diphtheria and 0.01 IU/ml for Tetanus. Conclusion The acellular combination Vaccine was immunogenic for diphtheria, Tetanus and pertussis components and was associated with low rates of fever following immunisation.
Manuela Fontanillo-fontanillo - One of the best experts on this subject based on the ideXlab platform.
-
The safety and efficacy of the Tetanus Vaccine intramuscularly versus subcutaneously in anticoagulated patients: a randomized clinical trial
BMC family practice, 2014Co-Authors: Fernando Isidro Lago-deibe, Maria-victoria Martín-miguel, Carmen Velicia-peñas, Isabel Rey Gómez-serranillos, Manuela Fontanillo-fontanilloAbstract:Background: In patients treated with oral anticoagulants, subcutaneous injections of anti-Tetanus Vaccine are usually recommended to reduce the risk of bleeding, although the effectiveness of the Vaccine has only been proven for intramuscular injection. The objective of this study was to compare the safety and efficacy of intramuscular and subcutaneous injections of Tetanus-diphtheria Vaccine in patients treated with oral anticoagulants. Methods/design: We present a prospective, double blinded, clinical trial comparing two groups of patients with oral anticoagulants: one group was administered Tetanus-diphtheria Vaccine by intramuscular injection, while the other was administered the same Vaccine by subcutaneous injection. Allocation to each group was randomized and the duration of the study was six years. Study population: all patients treated with oral anticoagulants, who had been administered with at least one dose of Vaccine, at 15 Health Centres in Vigo (Spain), and who agreed to participate in the study. The sample size was 115 patients in each group. The main variables for the safety analysis were the measurement of the brachial diameter, the appearance of basic injuries at the Vaccine administration site, the appearance of pain and systemic reactions. The variable used for the efficacy analysis was a significant increase in the titres of anti-Tetanus toxoid antibodies. An Intention-to-treat analysis will be performed. Details will be classified according to the administration route, while within each group a 3-tiered stratification will be defined by the administered number of doses. As a measure of association, relative risk will be estimated; the reduction of relative risk will also measured. For safety and to control the confounder effect, a logistic regression analysis will be carried out. As a measure of impact the reduction of absolute risk in relation to the total number of patients to be treated and the Number Needed to Treat will be estimated. CONSORT 2010 guidelines were applied for reporting parallel group randomised trials. Discussion: The most significant difficulties on the project are related to the large number of participating centres, required to obtain a viable study population sample size, and the coordination given the scattering of the centres and researchers.
F Bell - One of the best experts on this subject based on the ideXlab platform.
-
Adverse effects and sero-responses to an acellular pertussis/diphtheria/Tetanus Vaccine when combined with Haemophilus influenzae type b Vaccine in an accelerated schedule.
European journal of pediatrics, 1999Co-Authors: F Bell, Paul T. Heath, Jenny M. Maclennan, F Shackley, N Shearstone, Linda Diggle, C Thornton, H Griffiths, Er Moxon, Adam FinnAbstract:Acellular pertussis Vaccines provide protection against pertussis with few adverse effects. Differences in the reactogenicity and immunogenicity of available pertussis Vaccines may be influenced by the immunisation schedule employed. We assessed responses to an acellular pertussis, diphtheria, Tetanus Vaccine mixed with Haemophilus influenzae type b (Hib) Vaccine, (PRP-T) given at age 2, 3 and 4 months. Parents kept a symptom diary for 3 days after each immunisation. Antibodies to diphtheria, Tetanus, pertussis toxin and filamentous haemagglutinin were measured by enzyme immunoassay at 2 and 5 months. Results were compared with historical controls who received a combination whole-cell pertussis, diphtheria, Tetanus/PRP-T Vaccine in the same schedule. A total of 262 infants were recruited, of whom 251 were fully evaluated after three doses of Vaccine. Systemic and most local reactions were less frequent following the acellular combination. Fever ≥38°C was reported after only 0.6% of doses. Redness or swelling ≥2.5 cm were unusual after the first two doses (2–5%), but rates rose to 13% after the third dose. Antibody responses to diphtheria and Tetanus toxoids were lower, while those to pertussis antigens were higher, more uniform and less attenuated by pre-immunisation antibody than in infants who received the whole-cell combination. All infants achieved protective antibody titres of at least 0.1 IU/ml for diphtheria and 0.01 IU/ml for Tetanus.
-
Adverse effects and sero-responses to an acellular pertussis/diphtheria/Tetanus Vaccine when combined with Haemophilus influenzae type b Vaccine in an accelerated schedule
European Journal of Pediatrics, 1999Co-Authors: F Bell, F Shackley, N Shearstone, Linda Diggle, C Thornton, H Griffiths, Er Moxon, P. Heath, J. Maclennan, Adam FinnAbstract:Acellular pertussis Vaccines provide protection against pertussis with few adverse effects. Differences in the reactogenicity and immunogenicity of available pertussis Vaccines may be influenced by the immunisation schedule employed. We assessed responses to an acellular pertussis, diphtheria, Tetanus Vaccine mixed with Haemophilus influenzae type b (Hib) Vaccine, (PRP-T) given at age 2, 3 and 4 months. Parents kept a symptom diary for 3 days after each immunisation. Antibodies to diphtheria, Tetanus, pertussis toxin and filamentous haemagglutinin were measured by enzyme immunoassay at 2 and 5 months. Results were compared with historical controls who received a combination whole-cell pertussis, diphtheria, Tetanus/PRP-T Vaccine in the same schedule. A total of 262 infants were recruited, of whom 251 were fully evaluated after three doses of Vaccine. Systemic and most local reactions were less frequent following the acellular combination. Fever ≥38°C was reported after only 0.6% of doses. Redness or swelling ≥2.5 cm were unusual after the first two doses (2–5%), but rates rose to 13% after the third dose. Antibody responses to diphtheria and Tetanus toxoids were lower, while those to pertussis antigens were higher, more uniform and less attenuated by pre-immunisation antibody than in infants who received the whole-cell combination. All infants achieved protective antibody titres of at least 0.1 IU/ml for diphtheria and 0.01 IU/ml for Tetanus. Conclusion The acellular combination Vaccine was immunogenic for diphtheria, Tetanus and pertussis components and was associated with low rates of fever following immunisation.
C Von Hunolstein - One of the best experts on this subject based on the ideXlab platform.
-
Reactogenicity and immunogenicity of adult versus paediatric diphtheria and Tetanus booster dose at 6 years of age.
Vaccine, 2001Co-Authors: M L Ciofi Degli Atti, S Salmaso, B Cotter, G Gallo, G Alfarone, A Pinto, A Bella, C Von HunolsteinAbstract:We evaluated the reactogenicity and immunogenicity of a booster dose of diphtheria-Tetanus Vaccine administered at the age of school-entry, comparing a low-dose Vaccine (dT) to the standard paediatric dose (DT). Participants were randomly assigned to receive one of the two Vaccines; the study was evaluator-blinded. The frequency of side-reactions was similar when comparing the two groups, except when considering local redness and swelling, which were significantly more frequent among the DT group. The post-booster geometric mean titre of diphtheria antibodies in the DT group was twice as high as that in the dT group (14.1 IU/ml versus 7.7 IU/ml; P
Fernando Isidro Lago-deibe - One of the best experts on this subject based on the ideXlab platform.
-
The safety and efficacy of the Tetanus Vaccine intramuscularly versus subcutaneously in anticoagulated patients: a randomized clinical trial
BMC family practice, 2014Co-Authors: Fernando Isidro Lago-deibe, Maria-victoria Martín-miguel, Carmen Velicia-peñas, Isabel Rey Gómez-serranillos, Manuela Fontanillo-fontanilloAbstract:Background: In patients treated with oral anticoagulants, subcutaneous injections of anti-Tetanus Vaccine are usually recommended to reduce the risk of bleeding, although the effectiveness of the Vaccine has only been proven for intramuscular injection. The objective of this study was to compare the safety and efficacy of intramuscular and subcutaneous injections of Tetanus-diphtheria Vaccine in patients treated with oral anticoagulants. Methods/design: We present a prospective, double blinded, clinical trial comparing two groups of patients with oral anticoagulants: one group was administered Tetanus-diphtheria Vaccine by intramuscular injection, while the other was administered the same Vaccine by subcutaneous injection. Allocation to each group was randomized and the duration of the study was six years. Study population: all patients treated with oral anticoagulants, who had been administered with at least one dose of Vaccine, at 15 Health Centres in Vigo (Spain), and who agreed to participate in the study. The sample size was 115 patients in each group. The main variables for the safety analysis were the measurement of the brachial diameter, the appearance of basic injuries at the Vaccine administration site, the appearance of pain and systemic reactions. The variable used for the efficacy analysis was a significant increase in the titres of anti-Tetanus toxoid antibodies. An Intention-to-treat analysis will be performed. Details will be classified according to the administration route, while within each group a 3-tiered stratification will be defined by the administered number of doses. As a measure of association, relative risk will be estimated; the reduction of relative risk will also measured. For safety and to control the confounder effect, a logistic regression analysis will be carried out. As a measure of impact the reduction of absolute risk in relation to the total number of patients to be treated and the Number Needed to Treat will be estimated. CONSORT 2010 guidelines were applied for reporting parallel group randomised trials. Discussion: The most significant difficulties on the project are related to the large number of participating centres, required to obtain a viable study population sample size, and the coordination given the scattering of the centres and researchers.